SLC5A2 and chronic kidney disease: Current therapeutic strategies, including intensive lifestyle interventions and pharmacological approaches such as renin–angiotensin–aldosterone system inhibitors (RAASis) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) for managing blood pressure, glucose levels, and proteinuria, can partially slow the progression of chronic kidney disease (CKD).